Rambler Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 10 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 2.84%
- Profit Growth 37.87%
- Ebitda 12.51%
- Net Worth 101.53%
- Total Assets 44.65%
About Rambler Pharmaceuticals
Rambler Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 February 2015 and has a history of Ten years. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Tyagi and Sushit Rathi serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2015PTC276638
- Company No.
276638
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Feb 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Rambler Pharmaceuticals Private Limited offer?
Rambler Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Rambler Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Tyagi  | Director | 13-Feb-2015 | Current |
| Sushit Rathi | Director | 18-Jan-2017 | Current |
Financial Performance of Rambler Pharmaceuticals.
Rambler Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 2.84% increase. The company also saw a substantial improvement in profitability, with a 37.87% increase in profit. The company's net worth Soared by an impressive increase of 101.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rambler Pharmaceuticals?
In 2022, Rambler Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Redon Infra Power Private LimitedRahul Tyagi and Sushit Rathi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rambler Pharmaceuticals?
Unlock and access historical data on people associated with Rambler Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rambler Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rambler Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
